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Abstract 
Background: Cytauxzoonosis is a disease of felids in North America caused by the tick-transmitted apicomplexan 
parasite Cytauxzoon felis. Cytauxzoonosis is particularly virulent for domestic cats, but no vaccine currently exists. The 
parasite cannot be cultivated in vitro, presenting a significant limitation for vaccine development.
Methods: Recent sequencing of the C. felis genome has identified over 4300 putative protein-encoding genes. From 
this pool we constructed a protein microarray containing 673 putative C. felis proteins. This microarray was probed 
with sera from C. felis-infected and naïve cats to identify differentially reactive antigens which were incorporated into 
two expression library vaccines, one polyvalent and one monovalent. We assessed the efficacy of these vaccines to 
prevent of infection and/or disease in a tick-challenge model.
Results: Probing of the protein microarray resulted in identification of 30 differentially reactive C. felis antigens that 
were incorporated into the two expression library vaccines. However, expression library immunization failed to pre-
vent infection or disease in cats challenged with C. felis.
Conclusions: Protein microarray facilitated high-throughput identification of novel antigens, substantially increasing 
the pool of characterized C. felis antigens. These antigens should be considered for development of C. felis vaccines, 
diagnostics, and therapeutics.
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Background
Cytauxzoon felis is a tick-transmitted apicomplexan 
parasite that is the causative agent of cytauxzoonosis in 
domestic and wild felids in North and South America 
[1–8]. A closely related, genetically unique Cytauxzoon 
sp. has been identified in Europe [9–13], but has not 
been associated with classic cytauxzoonosis which is 
characterized by high mortality rates and massive prolif-
eration and vascular dissemination of schizont-infected 
myeloid cells. Although no longer considered uniformly 
fatal in domestic cats, morbidity and mortality remain 
high for individuals presenting with acute cytauxzoono-
sis [14–19]. Even with treatment, which can cost thou-
sands of dollars, mortality remains at least 40% [20]; a 
vaccine is not currently available. Following its initial 
discovery in Missouri in 1976, C. felis has since been 
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detected in domestic cats in 19 states [6, 8, 21, 22] and in 
bobcats in two additional states [23, 24]. The prevalence 
of C. felis infections in enzootic regions of the USA has 
been reported at 6.2% [17], which is higher than the esti-
mated prevalence rates of common infections like feline 
leukemia virus (2.26%) and feline immunodeficiency 
virus (4.2%, Companion Animal Parasite Council, https 
://capcv et.org/maps/#2017/all/felv/cat/unite d-state s/, 
https ://capcv et.org/maps/#2017/all/fiv/cat/unite d-state 
s/). This pattern could be due to a combination of fac-
tors, including an increase in feline reservoirs, expanding 
range of competent tick vectors (Amblyomma america-
num and Dermacentor variabilis), and increased clinician 
awareness and diagnosis.
Prevention of cytauxzoonosis appears to be the optimal 
control strategy, and currently depends either on appli-
cation of prophylactic acaricides [25], or keeping cats 
indoors. However, in practice, these strategies are flawed. 
Despite recommendations to house cats indoors, an esti-
mated 35–60 million pet cats are still allowed to roam 
outdoors in the United States [26, 27]. Furthermore, 
effective acaricide prophylaxis may be limited by lack of 
owner compliance or cost of acaricides, as a recent study 
indicated as few as 38% of cats presenting to a veteri-
nary teaching hospital had not received any form of tick 
prevention [28]. We therefore propose that vaccination 
against C. felis would serve as a practical and cost-effec-
tive method of prevention. Because cytauxzoonosis is 
highly pathogenic, a vaccine that reduces morbidity and 
mortality, even if it failed to prevent infection, would be 
considered successful.
There is some evidence that domestic cats can develop 
a protective immune response against C. felis. Previous 
studies have demonstrated that cats that survive acute 
cytauxzoonosis are protected from clinical disease fol-
lowing subsequent challenge with a lethal dose of viru-
lent C. felis [4, 29–31]. However, antigen discovery and 
vaccine development have been hindered by the inability 
to cultivate C. felis in vitro. To redress this we previously 
sequenced and annotated the C. felis genome, and under-
took a search for vaccine candidates [32] via an approach 
known as “reverse vaccinology” [33]. The underlying 
premise is that each of the 4300 putative proteins that 
were predicted [32] could represent a potential vaccine 
candidate. To date, a single C. felis vaccine candidate has 
been identified and characterized using a single candi-
date gene approach [32]. Although identification of can-
didates in such fashion is conceptually straightforward, 
this approach is both labor-intensive and cost-prohibi-
tive when considering the number of inferred protein-
encoding genes present in the C. felis genome. As a more 
efficient strategy, we deployed a protein microarray to 
screen a large number of C. felis proteins for antigenicity. 
Protein microarray technology has been utilized as a 
strategy for identification and assessment of diagnos-
tic and/or vaccine candidates for a variety of pathogens, 
including protozoal organisms [34–39] as well as fastidi-
ous organisms that have not been cultivated in vitro [40, 
41]. Conceptually similar, an alternative, high through-
put method for screening antigens as vaccine candidates 
in vivo is a DNA expression library immunization (ELI) 
approach. This entails immunization of individuals with a 
library of expression plasmids containing either a portion 
of or the entire genome of the infectious agent [42–44]. 
ELI has been used to identify protective antigens against 
a variety of protozoal infections in mice, including Plas-
modium, Leishmania, and Trypanosoma species [42, 
45–49].
Our goal was to develop a low-cost, fast-track approach 
for vaccine development that could be used for patho-
gens that are difficult to isolate/culture or for which there 
is limited funding available. The aims of this study were 
twofold. First, we described the utilization of a C. felis 
protein microarray for identification of antigens. Then we 
assessed the ability of these antigens to induce protection 
from clinical disease via ELI. Protein microarray success-
fully identified 30 C. felis antigens. However, ELI using 
these antigens failed to induce protection against dis-
ease or infection. Collectively, these data provide insight 
into the humoral immune response against C. felis, and 
help build a foundation for future vaccine development 
against C. felis.
Methods
Cytauxzoon felis DNA isolation, RNA isolation and cDNA 
synthesis
Cytauxzoon felis genomic DNA was extracted from 
leukoreduced blood (Purecell NEO Neonatal High 
Efficiency Leukocyte Reduction Filter for Red Cell 
Aliquots, PALL Corp., Port Washington, NY) using a 
commercially available kit (QIAamp DNA Blood Mini 
Kit Qiagen, Valencia, CA). RNA was extracted from 
liver tissue of a cat infected with C. felis using a com-
mercially available kit (ZR Tissue and Insect RNA Kit, 
Zymo Research, Irvine, CA). Using this RNA as tem-
plate, cDNA was synthesized with Taqman Reverse 
Transcription Reagents following the two step RT-
PCR protocol according to manufacturer’s instructions 
(Roche, Mannheim, Germany).
Identification and selection of Cytauxzoon felis genes/ORFs
Of the 4378 predicted C. felis proteins [32], we selected 
864 as candidates (Additional file  1: Supplementary 
Data Set 1) to assess via protein microarray based on 
at least one of the following criteria: genomic synteny 
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and/or sequence homology to antigenic proteins identi-
fied in related protozoal organisms; sequence homology 
to Plasmodium proteins that displayed heterologous 
reactivity against serum from cats infected with C. felis 
(data not shown); or the presence of putative features 
predicted in silico to increase antigenicity, including 
the presence of predicted signal peptides, transmem-
brane domains, and predicted antigenic sites (Signal P 
Server v.4.0 and TMHMM Server v.2.0 from the Center 
for Biological Sequence Analysis). Of the genes/ORFs 
encoding the 864 putative proteins, those that were 
126–3804  bp in length were selected for amplification 
for inclusion on the protein microarray (768/864).
PCR amplification of linear acceptor vectors (pXT7 
and PVAX1)
We used high throughput homologous recombina-
tion to clone target genes for expression on the protein 
microarray (pXT7) and for incorporation into DNA 
vaccines (pVAX1). Linearized pXT7 was produced and 
amplified using previously described methods [50] with 
the following modification: Roche high-fidelity enzyme 
mix (2.5 U) and a 1X concentration of Expand high-
fidelity buffer with  MgCl2 was utilized (Roche, Man-
nheim, Germany).
Linearized pVAX1 (Invitrogen, Carlsbad, CA) was pro-
duced using identical methods as for pXT7. Primers were 
designed to amplify the linear acceptor vector and incor-
porate a Kozak sequence upstream of the cloning site 
and a stop codon downstream of the coding site (Addi-
tional file 2: Supplementary Table 1). The 25 μL reaction 
consisted of 1 ng of linearized pVAX1, 25 pmols of each 
primer (Forward: 5′-TAG ATC CAC TAG TCC AGT GTG-
3′, Reverse: 5′-CCA TGG TGG CCG AGC TCG GTA CCA 
AGC-3′), 5 pmol of dNTPs, 1.155 U of Expand high-fidel-
ity enzyme mix, and a 1X concentration of Expand high-
fidelity buffer with  MgCl2 (Roche, Mannheim, Germany). 
Thermal cycling conditions consisted of an initial dena-
turation step at 95  °C for 5  min, followed by 35 ampli-
fication cycles (94  °C for 20 s, 50  °C for 30 s, and 68  °C 
for 3.5 min) and a final extension step at 72 °C for 5 min 
(Techne Inc., Burlington, NJ).
PCR amplification of Cytauxzoon felis genes/ORFs 
for protein microarray and DNA vaccine
For genes/ORFs included on protein microarray, we 
designed primers that included cassettes homologous 
cloning sites of the linearized pXT7 (Forward cassette: 
5′-ACG ACA AGC ATA TGC TCG AG-3′, Reverse cassette: 
5′-TCC GGA ACA TCG TAT GGG TA-3′); ORFs that were 
larger than 3000 bp were split into smaller fragments as 
needed for efficient amplification. Each 50  μL reaction 
contained 1  μL of genomic C. felis DNA template or 
cDNA, 50  pmol of each primer, 10  nmol of deoxynu-
cleoside triphosphates (dNTPs), 2.5 U of Expand high-
fidelity enzyme mix, and a 1X concentration of Expand 
high-fidelity buffer with  MgCl2 (Roche, Mannheim, Ger-
many). Thermal cycling conditions consisted of an initial 
denaturation step at 95 °C for 5 min, followed by 40–45 
amplification cycles (95 °C for 30 s, 55 °C for 15 s, 50 °C 
for 15 s, and 68 °C for 3 min) and a final extension step at 
68 °C for 10 min (Techne Inc., Burlington, NJ).
Similarly, for candidates included in the DNA vaccine, 
we designed primers with cassettes homologous to clon-
ing sites of pVAX1 (Forward cassette: 5′-ACC GAG CTC 
GGC CAC CAT GG-3′, Reverse cassette: 5′-CAC ACT 
GGA CTA GTG GAT CTA-3′). Each 25  μL reaction con-
tained 1 μL of genomic C. felis DNA template or cDNA 
(Additional file  2: Supplementary Table  1), 25  pmol of 
each primer, 5  nmol of dNTPs, 1.75 U of Expand high-
fidelity enzyme mix, and a 1X concentration of Expand 
high-fidelity buffer with  MgCl2 (Roche, Mannheim, Ger-
many). Thermal cycling conditions consisted of an ini-
tial denaturation step at 94 °C for 5 min, followed by 40 
amplification cycles (94 °C for 30 s, 55 °C for 15 s, 50 °C 
for 15 s, and 68 °C for 4 min) and a final extension step at 
68 °C for 7 min (Techne Inc., Burlington, NJ).
PCR conditions were optimized for individual genes/
ORFs as needed, and amplicons were confirmed by gel 
electrophoresis for correct size prior to proceeding to 
homologous recombination.
High throughput homologous recombination cloning
All successfully amplified genes/ORFs were cloned into 
the appropriate plasmid expression vector (pXT7 for 
the microarray or pVAX1 for DNA vaccine) using a high 
throughput PCR recombination cloning method as pre-
viously described [50]. While the majority of plasmids 
cloned with pXT7 for the protein microarray were iso-
lated without colony selection as described [50], colony 
selection was utilized for those plasmids cloned with 
pVAX1 for the DNA vaccine. Minipreps of clones were 
confirmed to have the correct insert via PCR using 
ORF sequence-specific primers and/or bi-directionally 
sequencing using T7 and BGH reverse primers; inter-
nal sequencing primers were designed and utilized as 
needed to obtain complete bi-directional sequencing 
(MCLAB, South San Francisco, CA).
Protein microarray printing
The expression of successfully cloned genes/ORFs was 
carried out for 5 h via in vitro transcription-translation 
(IVTT) according to manufacturer’s directions (RTS E. 
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coli HY 100 kit, biotechrabbit GmbH, Germany) with 
addition of 0.067 mM Brij-98. A selection of ORFs that 
were predicted to be soluble (n = 137) were expressed in 
duplicate and transferred to plates without addition of 
Brij-98. Crude proteins were printed immediately with-
out purification on nitrocellulose-coated glass NOVA 
slides (Grace Bio Labs, Bend, Oregon 97702) using an 
OmniGrid 100 microarray printer (GeneMachines, 
San Carlos, CA). Controls spotted onto chips included 
IVTT reactions without plasmid and purified IgG, and 
protein expression was confirmed by probing for poly-
histidine (clone His-1, Sigma) and hemagglutinin tags 
(clone 3F10, Roche) included within the PXT7 vector.
Protein microarray probing
Serum was collected from 48 cats throughout the United 
States (20 cats PCR positive for C. felis, 20 cats PCR nega-
tive for C. felis, and 8 SPF cats that were PCR negative for 
C. felis). All 20 infected cats were known to have survived 
acute cytauxzoonosis. Four of these C. felis infected cats 
were known to be acutely infected and 4 were chronically 
infected.
Sera were diluted to 1:200 in Protein Array Block-
ing Buffer (GVS, Sanford, ME) with 10% (vol/vol) E. coli 
lysate and incubated at room temperature for 30  min. 
Blocking anti-E. coli antibodies in the serum samples 
with E. coli lysate helps reducing background reactivity 
against E. coli proteins from IVTT reactions. Arrays were 
rehydrated in Protein Array Blocking Buffer and incu-
bated in sera overnight at 4  °C with constant agitation. 
Slides were then rinsed 10 mM Tris buffer (TBS, pH 8.0) 
containing 0.05% Tween-20 (TTBS), then incubated in 
biotin-conjugated, goat anti-cat immunoglobulin (anti-
IgGfcc, Jackson Immuno Research, West Grove, PA) 
diluted 1/200 in blocking buffer. After rinsing the slides, 
bound antibodies were detected by incubation with 
streptavidin conjugated SureLightH P-3 (Columbia Bio-
sciences, Frederick, MD). The slides were then washed 
three times in TTBS and three times in TBS followed by 
a final water wash. The slides were air dried after brief 
centrifugation and analyzed using a Perkin Elmer Sca-
nArray Express HT microarray scanner (Waltham, MA).
Protein microarray statistical analysis
The protein microarrays used here do not meet the cri-
teria for required deposition under MIAME guidelines 
[51], and alternatives to standardize protein microarray 
results are in development to insure that all informa-
tion can be easily interpreted (description of minimum 
information about a proteomics experiment [MIAPE] 
can be found here [52]). Intensities were quantified using 
QuantArray software utilizing automatic local back-
ground subtraction for each spot. ‘‘No DNA’’ controls 
consisting of E. coli IVTT reactions without addition of 
plasmid were averaged and used to subtract background 
E. coli reactivity from the unmanipulated raw data. All 
results presented are expressed as signal intensity. As 
previously reported [53], the ‘‘vsn’’ package in the Bio-
conductor suite (http://Bioco nduct or.org/) in the R sta-
tistical environment (http://www.R-proje ct.org) was used 
to calculate seroreactivity. In addition to the variance 
correction, this method calculates maximum likelihood 
shifting and scaling calibration parameters for different 
arrays, using known non-differentially expressed spots. 
This calibration has been shown to minimize experi-
mental effects [54]. We used raw values for the positive 
and negative controls to calibrate, and then normalize, 
the entire data set using the vsn package. Antigens were 
considered to be reactive if signal intensities were greater 
than the average signal intensity of the “No DNA” control 
spots, plus 1.5-times the standard deviation. Differential 
analysis of the normalized signals was then performed 
using a Bayes-regularized t test adapted from Cyber-T 
for protein arrays [55–58]. Benjamini–Hochberg p value 
adjustments were applied to account for multiple test 
conditions [59]. All p values shown are Benjamini–Hoch-
berg corrected for false discovery.
In silico analysis of antigens selected for inclusion 
in vaccines
A total of 33 different C. felis antigens printed on the pro-
tein microarray were chosen for inclusion two DNA vac-
cines (Table  1). Each candidate was assessed for amino 
acid sequence similarity to other Piroplasmida proteins 
via BLAST search (blastx) against Theileria and Babe-
sia species genomes (PiroplasmaDB, http://pirop lasma 
db.org/piro/), Plasmodium species genomes (PlasmoDB, 
http://plasm odb.org/plasm o/), or all banked nucleo-
tide sequences in the National Center for Biotechnology 
Information (NCBI, https ://blast .ncbi.nlm.nih.gov/Blast 
.cgi).
Production of vaccines
Individual colonies confirmed to contain plasmids of 
interest were selected and grown in 150 mL LB/kanamy-
cin (50 µg/mL) and were isolated according to manufac-
turer’s instructions (Zyppy Plasmid Maxiprep Kit, Zymo 
Research, Irvine, CA) or were commercially prepared 
(Genewiz, South Plainfield, NJ). Multiple maxiprepara-
tions were performed as needed to attain the desired 
final amount of plasmid. Plasmids were further concen-
trated by ethanol precipitation as necessary and were 
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resuspended in endotoxin-free tissue culture grade dis-
tilled water (Thermo Fisher Scientific, Waltham, MA).
Two different vaccines were developed: “CF-Library” 
and “CF-1.” CF-Library consisted of 32 candidates, while 
CF-1 consisted of both the carboxy-terminal region and 
full-length C. felis cf76 (Additional file 2: Supplementary 
Table  1) [32]. Each vaccine dosage contained a total of 
1 mg of DNA. CF-1 contained 500 μg each of C-terminal 
region cf76 and full-length cf76, while CF-Library con-
tained 31.25 μg of each of the 32 plasmids.
Animals
Eighteen, 11–18  month old, intact female purpose bred 
cats that were PCR negative for C. felis were obtained 
from a commercial supplier (Liberty Research, Inc., 
USA). Cats were cared for according to the principles 
outlined in the National Institutes of Health Guide for 
the Care Use of Laboratory Animals and were housed 
in AAALAC accredited facilities within sealed, climate-
controlled isolation rooms with 12  h light/dark cycles. 
All animal use was approved by the University of Mis-
souri Animal Use and Care Committee (protocol number 
7909).
Vaccine study design
Cats were randomly assigned to test and control groups, 
which are summarized in Additional file  3: Supplemen-
tary Fig. 1. Seven cats received vaccines: three cats (331, 
623, and 638) received CF-1 and four cats (77, 308, 339, 
and 835) received CF-Library. Investigators were blinded 
to whether vaccinated cats received CF-Library or CF-1. 
Eleven cats did not receive vaccines: eight of these were 
infected with C. felis (positive controls for infection) and 
three were infested with C. felis-naïve ticks (negative con-
trols for infection). Unvaccinated cats were also simulta-
neously enrolled in separate studies testing the efficacy 
of novel chemotherapeutics against cytauxzoonosis and 
the immune response to tick infestation and/or C. felis 
infection.
The schedule of vaccination and infection is summa-
rized in Additional file  4: Supplementary Fig.  2. Cats 
within both vaccine test groups received three intramus-
cular (IM) injections. For the first two vaccinations (Day 
6 and Day 30), cats received 1 mg of DNA (0.7 mL vol-
ume) via needle and syringe in the left (Day 6) or right 
(Day 30) cranial thigh (quadriceps femoris muscle). The 
third and final vaccination (1 mg of DNA in 0.25 mL) was 
administered on Day 50 in the caudal medial right thigh 
via VET JET transdermal vaccination system (Merial, 
Inc., Athens, Georgia). When using the VET JET device, 
cats were sedated with dexdomitor (15–20  ug/kg) and 
acepromazine (0.1 mg/kg) delivered intravascularly (IV).
Challenge model
Cats were infected with C. felis 59 days after initial vacci-
nation (Additional file 4: Supplementary Fig. 2) using tick 
transmission as previously described [25]. Uninfected 
cats were identically infested with C. felis-naïve ticks. For 
tick infestation, cats were anesthetized as described for 
transdermal vaccination above. Ticks were removed from 
cats 10–13 days post infestation, and the number of free 
and attached ticks as well as subjective engorgement of 
ticks were recorded for each cat (Additional file 5: Sup-
plementary Table 2).
Clinical evaluation
Once infected cats were inspected at least four times 
a day. Physical exams were performed daily, and atti-
tude, heart rate, respiratory rate, and body temperature 
(measured rectally or by subcutaneous temperature chip 
(IPTT-3000, Bio Medic Data Systems, Seaford, DE)) were 
recorded 2–4 times daily.
Starting at 12  days post-infection and finishing at the 
resolution of clinical symptoms or death, blood was col-
lected from each cat via the jugular vein or a subcuta-
neous venous access port (VAP; CompanionPort CP4, 
Access Technologies, Skokie, IL). Blood was collected 
into EDTA for complete blood count (CBC; Sysmex 
XT2000i V Automated Hematology Analyzer) and into 
red top tubes for serum biochemical profile (Olympus 
400AUe Chemistry Analyzer). Frequency of hematologic 
and biochemical testing performed for each individual 
cat was dictated by severity of illness and discretion 
of attending veterinarian but was generally performed 
every-other-day, and peaks and/or nadirs of clinico-
pathologic parameters were compared.
Therapeutic intervention
Supportive care and/or antiprotozoal therapy was initi-
ated on a case by case basis at the discretion of attending 
veterinarian based on assigned treatment group (unvac-
cinated infected cats) or at the discretion of attending 
veterinarian if treatment was unassigned (vaccinated 
cats). Specific supportive therapies administered varied 
between cats and were tailored to the clinical needs of 
the individual (Additional file 6: Supplementary Table 3). 
Three different antiprotozoal treatment regimens were 
utilized in this study: two were experimental therapies 
that were administered to unvaccinated infected cats as 
a part of a separate study (Additional file 3: Supplemen-
tary Fig. 1). Experimental therapies included either Coar-
tem [20  mg artemether + 120  mg lumefantrine/tablet 
(Novartis), 2 tablets BID for 3 days] or a combination of 
4 oral antibiotics, referred to through the study as “4X 
Abx” (pradofloxacin 7.5 mg/kg q24 h, doxycycline 10 mg/
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kg q12  h, metronidazole 25  mg/kg q12  h, clindamycin 
10 mg/kg q12 h until clinical improvement). For any cat 
that developed advanced cytauxzoonosis despite vaccina-
tion or experimental treatments, atovaquone (Mepron, 
GlaxoSmithKline) and azithromycin was administered as 
previous described [20].
Assessment of infection, disease, and survival
Infection was confirmed by PCR amplification of para-
site DNA (ITS-1 and/or 18S) as previously described 
[60–62] and if possible by identification of parasites via 
microscopic evaluation of blood smears. Cytauxzo-
onosis was defined as cats being febrile (body tempera-
ture ≥ 102.5  °F) and having at least one of the following 
three biochemical/hematological abnormalities: hyper-
bilirubinemia (> 0.3  mg/dL), neutropenia (< 2.5  ×  103 
segmented neutrophils/µL), or thrombocytopenia 
(< 300 × 103 platelets/µL). Survival rates of groups were 
compared using the Freeman Halton extension [63] of 
the Fisher exact probability test with significance set at 
p ≤ 0.05 (VassarStats, Poughkeepsie, NY).
Assessment of humoral responses post vaccination 
and challenge
After the completion of the clinical trial portion of the 
vaccine pilot study, C. felis protein microarrays were 
probed as described above with sera obtained from cats 
from each test group. Sera were collected from vacci-
nated cats at 5–7 different time points throughout the 
study and were frozen at − 80 °C until protein microarray 
analysis (Additional file 4: Supplementary Fig. 2).
Results
Construction and quality assessment of Cytauxzoon felis 
protein microarray
Of the 864 C. felis genes/ORFs initially selected for 
analysis, 96 ORFs were excluded from further study due 
to small size and predicted minimal antigenicity and 
48 ORFs were unable to be PCR amplified, leaving 720 
genes/ORFs amplified for cloning. Of these, 15 were una-
ble to be cloned, and 32 had an incorrectly-sized insert 
in the pXT7 plasmid, leaving a total of 673 proteins for 
printing on the protein microarray (93.5% cloning effi-
ciency). Of these proteins, 633 proteins (94.07%) were 
efficiently expressed as determined by dual positive sig-
nals against the amino-terminal HIS and carboxy-termi-
nal hemagglutinin (HA) tags.
Identification of C. felis antigens and selection of vaccine 
candidates
The antibody response profile to C. felis proteins in 
infected, uninfected, and SPF domestic cats is shown as 
a heatmap in Fig. 1. Of the total 673 genes/ORFs probed, 
a total of 38 (5.6%) were found to be seroreactive to feline 
serum. Of these, 30 were differentially reactive to serum 
from C. felis infected cats (p < 0.05) and 8 were cross-
reactive to both infected and uninfected feline serum 
(p > 0.05). The number of infected and uninfected cats 
reacting to differentially reactive and cross-reactive pro-
teins is summarized in Table 2.
Protein features of the 30 differentially reactive pro-
teins include 21 proteins with a predicted signal peptide 
and 21 proteins with at least one and up to 11 predicted 
transmembrane domains (Table 1). All 30 proteins were 
predicted to have at least two and up to 52 antigenic sites 
(Table  1). Of these 30 proteins, four had been selected 
for placement on the microarray due to known orthol-
ogy with antigenic proteins from related organisms 
(Table 1). One protein was selected due to homology to 
a conserved Plasmodium protein that previously showed 
reactivity against serum from C. felis infected cats (data 
not shown, Table  1). The remaining 25 proteins were 
selected for placement on the protein microarray primar-
ily due to in silico predicted antigenicity, but on further 
investigation at least 15 of these proteins showed some 
degree of orthology to proteins from related organisms 
(Table  1). Ultimately, all 30 of the differentially reactive 
proteins were selected for incorporation into CF-Library 
(Table 1).
One cross-reactive protein was also selected for inclu-
sion into CF-Library (Elongation Factor-1  orthologue). 
This protein was nearly classified as being differentially 
reactive (p = 0.052, Fig. 1), and was differentially reactive 
on a heterologous microarray screening sera from C. felis 
infected cats against Plasmodium falciparum antigens 
(Candidate 31, Table 1).
Of the infected feline serum samples, four were known 
to be collected while the cat was suffering from acute 
cytauxzoonosis, while four were known to be collected 
> 1  year after resolution of disease but while the cat 
remained persistently parasitemic. The antibody response 
profile to C. felis proteins in these samples were com-
pared to assess for kinetic changes in serologic profile 
against C. felis (Additional file 7: Supplementary Fig. 3). 
A total of 52 proteins were found to be reactive (signal 
intensity > 1.5X No DNA standard deviation) to sera from 
either acute or chronically infected cats. No significant 
difference was seen (p > 0.05) for any proteins when com-
paring reactivity between serum of chronically or acutely 
infected cats. The majority of the proteins (n = 50) had 
a higher average reactivity against sera from chronically 
infected cats. However, two proteins had a higher average 
reactivity against sera from acutely infected cats (Addi-
tional file  7: Supplementary Fig.  3). These two proteins 
were also selected for inclusion in CF-Library (Candi-
dates 32–33, Table 1).
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Vaccination and challenge
Of the 33 C. felis genes/ORFs selected for ELI, 32 were 
successfully cloned into the expression plasmid pVAX1 
(97% cloning success rate; Table 1). Both developed vac-
cines (CF-Library and CF-1) were delivered successfully 
to cats (no significant volume loss during administra-
tion), with no adverse clinical effects observed post-vac-
cination (Additional file 4: Supplementary Fig. 2).
All cats infested with C. felis positive ticks met the cri-
teria for both infection and cytauxzoonosis (Table  3), 
with the majority (n = 13/15 infected cats) exhibiting at 
least two of the three biochemical/hematological abnor-
malities that were considered disease-defining. No para-
sites were detected for cats infested with C. felis-naïve 
ticks and those cats did not develop cytauxzoonosis.
Fig. 1 Cytauxzoon felis protein microarray identifies 30 differentially reactive antigens and 8 cross-reactive antigens. Serologic reactivity of antigens 
are depicted as a heatmap in a. Antigens are listed in rows while grouping of individuals are denoted in columns. Average signal intensity of 
individual antigens against serum from different groups are depicted in b 
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With the exception of one cat vaccinated with CF-
Library, all infected cats received supportive care and 
antiprotozoal therapy (Table 3, Additional file 6: Supple-
mentary Table 3). None of the uninfected cats became ill 
or required treatment (Table 3).
Survival of individual cats is summarized in Fig. 2 and 
Table  3. Survival rate of the infected cats vaccinated 
against CF-Library was 100% (4 out of 4 cats survived). 
Survival rate of the infected cats vaccinated against 
CF-1 was 33% (1 out of 3 cats survived). Survival rate of 
the unvaccinated infected cats was 75% (6 out of 8 cats 
Table 2 Summary of the number of cats with reactivity to differentially and cross reactive antigens
Antigens are listed in order of descending average seroreactivity against C. felis-infected serum
Order of reactivity Location in C. felis genome Number of infected cats 
with + reaction
Number of uninfected 
cats with + reaction
Differentially reactive
1 contig00088:95434-96586(−) 20 2
2 contig00034:39570-41574(+) 19 1
3 contig00195:8035-8711(+) 20 3
4 contig00109:22439-22690(+) 16 1
5 contig00259:2101-4206(−) 17 0
6 contig00010:254-1016(+) 18 0
7 contig00147:58097-59225(−) 16 0
8 contig00411:10993-12107(+) 14 0
9 contig00029:68709-70041(+) 14 0
10 contig00237:32067-33665(+) 16 0
11 contig00086:6446-7270(−) 15 0
12 contig00046:25575-26421(−) 15 0
13 contig00119:20915-22637(−) 11 0
14 contig00260:69016-71962(+) 14 2
15 contig00052:839-1019(+) 10 1
16 contig00071:75760-77446(+) 11 3
17 contig00006:15286-16508(+) 10 1
18 contig00156:32608..32875(−) 14 1
19 contig00195:6540-8711(+) 11 0
20 contig00214:29581-33385(+) 10 0
21 contig00047:67240-68739(+) 11 0
22 contig00093:7841..7964(+) 11 0
23 contig00130:22711..24075(−) 12 0
24 contig00137:10059-13245(−) 6 0
25 contig00088:68222-69173(−) 7 0
26 contig00232:10901..11056(−) 8 0
27 contig00433:34958-36380(+) 10 0
28 contig00147:21973-23388(+) 9 0
29 contig00145:9-1059(−) 7 0
30 contig00167:23417-24638(−) 8 0
Cross reactive
1 contig00123:201-1591(−) 5 1
2 contig00063:31158-31905(−) 10 1
3 contig00425:16748-17828(+) 6 1
4 contig00211:3458-4367(+) 6 0
5 contig00208:8686-10858(−) 7 7
6 contig00193:19970-21975(+) 8 1
7 contig00013:32266-33125(+) 5 0
8 contig00121:52751-54107(−) 3 0
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survived). Survival rate of uninfected cats was 100% (3 
out of 3 cats survived). However, there was no significant 
difference between survival rates of groups (p > 0.05).
Retrospective serological profiles of individual cats 
in response to vaccination and challenge
The serological responses of individual cats to vaccina-
tion varied (Additional file 8: Supplementary Fig. 4). Five 
cats (all cats vaccinated with CF-Library, one cat vacci-
nated with CF-1) developed a positive response to at least 
one antigen that they were vaccinated against prior to 
infection with C. felis (Table 4, Additional file 8: Supple-
mentary Fig. 4). Two cats (two cats vaccinated with CF-1) 
failed to develop a positive response to any antigens vac-
cinated against prior to infection with C. felis, and in 
fact, these two cats only developed positive responses to 
antigens that they were not vaccinated against, including 
Candidates 4, 15, and 31 (Table 4, Additional file 8: Sup-
plementary Fig. 4).
Additionally, all seven vaccinated cats developed a 
positive response to Candidate 31 (Elongation factor-1) 
regardless of what they were vaccinated against, making 
it unclear whether the increase in seroreactivity against 
this candidate was C. felis-specific or not. When disre-
garding the positive responses against Candidate 31, only 
two cats developed positive responses against any other 
antigens they were vaccinated against. These included a 
positive response against either partial length cf76 (Cat 
623, CF-1) or both partial and full length cf76 (Cat 77, 
CF-Library).
Discussion
This study describes the construction and probing of a 
Cytauxzoon felis protein microarray for identification of 
antigenic proteins, the subsequent incorporation of those 
antigens into two expression library vaccines, and the 
evaluation of those vaccines to prevent clinical disease in 
cats challenged with C. felis infection. Using these meth-
ods, we were able to identify a pool of 30 C. felis antigens 
using the protein microarray, but were not able protect 
cats from developing cytauxzoonosis through ELI.
This study further validates protein microarray as a 
valuable tool for high throughput antigen discovery for 
organisms that are unable to be cultured in  vitro. Prior 
to this study, only a single antigenic protein (cf76), which 
was identified by genome synteny with related organisms, 
had been characterized from a genome containing over 
4300 putative proteins [32]. By use of the protein micro-
array, we were able to rapidly discover 30 new C. felis 
antigens (Fig. 1).
In this study only a portion (673/4378 = 15.4%) of the 
putative protein-encoding genes in the C. felis genome 
were analyzed. The percentage of differentially seroreac-
tive proteins, 4.5% (30/673), was similar to percentages 
identified in other pathogens [34, 40, 64–67]. The pool of 
673 proteins was chosen using methods to maximize the 
likelihood of identifying antigenic proteins. Studies eval-
uating the antigenicity of the remaining 3705 putative C. 
felis proteins should be the focus of future studies.
A limitation to this approach is that antigens identi-
fied by protein microarray are restricted to those that 
elicit a humoral immune response. Protection against C. 
felis is likely to require both a cell-mediated and humoral 
immune response, as the parasite resides intracellu-
larly in the feline host. Unfortunately, high throughput 
methods for the identification of antigens that stimulate 
T-cells have only recently emerged, and are not cost-
effective or widely available, particularly for use in a feline 
system [35, 68–70]. It has been suggested that proteins 
that induce a cellular immune response are also likely to 
be recognized by serum antibodies [36]. Therefore the 
antigens identified in this study should also be assessed 
for T-cell reactivity.
Unfortunately, ELI using antigens identified on the 
protein microarray in this study did not prevent C. felis 
infection or clinical disease (cytauxzoonosis). There are 
a number of possible explanations why ELI failed in this 
study. First, it is possible that failure occurred in any 
number of the steps required for a DNA vaccine to effec-
tively confer immunity. This could include plasmid deliv-
ery into cells, expression of the antigens by the host cell, 
presentation of peptides on MHC molecules, and ade-
quate stimulation of both innate and adaptive immune 
responses [42, 71]. Alternatively, vaccination could be 
Fig. 2 Cats vaccinated with CF-Library have a higher survival rate 
(100%) than other infected cats. Cats vaccinated with CF-1 had a 
33% survival rate and unvaccinated, infected cats had a survival rate 
of 75%. Unvaccinated, uninfected cats also had a 100% survival rate 
(data not shown). DPI days post infection
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ineffective due to inadequacies in dose, delivery route, 
vector, composition (lack of adjuvant), or vaccination 
schedule. Some of these deficiencies could be identified 
and overcome by assessing efficacy and immunogenicity 
of ELI (e.g. muscle biopsy to confirm plasmid expression, 
identifying uniform seroconversion) prior to challenge.
Second, it is possible that the antigens included in the 
vaccines were unable to induce a protective immune 
response against C. felis. First, recognition of a protein by 
antibodies does not definitively indicate a protective B-cell 
response [35, 36]. Furthermore, as stated previously, even 
if a B-cell response is generated, humoral immunity alone 
may not induce protection from disease. Additionally, 
antibodies against some of these proteins (e.g. Candi-
date 31, or elongation factor-1) may not represent a C. 
felis-specific immune response. Instead, it may represent 
production of cross-reactive antibodies against other path-
ogens (e.g. Coccidia), as it has been previously shown that 
serological cross-reactivity occurs between Coccidia and 
hemoprotozoan parasites [72, 73]. The increase in sero-
reactivity against these proteins (Additional file  8: Sup-
plementary Fig. 4) could represent non-specific increases 
secondary to vaccination, which has previously been 
reported for other feline protozoan parasites [74].
We were attempting to develop a low-cost, fast-track 
approach for the development of a vaccine against a 
Table 4 Cats rarely seroconvert against antigens included in vaccine prior to infection with Cytauxzoon felis 
Candidates included in CF-1 are grouped at the top of the table (19 and 3). Individual cat numbers are listed below respective vaccine group. Y = Yes, N = No, number 
next to Y indicates day of seroconversion
Candidate Gene/ORF CF-1 CF-Library
331 623 638 77 308 339 835
19 contig00195:6540-8711(+) N N N Y—65 N N N
3 contig00195:8035-8711(+) N Y—30 N Y—30 N N N
1 contig00088:95434-96586(−) N N N N N N N
2 contig00034:39570-41574(+) N N N N N N N
4 contig00109:22439-22690(+) N Y—30 N N N N N
5 contig00259:2101-4206(−) N N N N N N N
6 contig00010:254-1016(+) N N N N N N N
7 contig00147:58097-59225(−) N N N N N N N
9 contig00029:68709-70041(+) N N N N N N N
10 contig00237:32067-33665(+) N N N N N N N
11 contig00086:6446-7270(−) N N N N N N N
12 contig00046:25575-26421(−) N N N N N N N
13 contig00119:20915-22637(−) N N N N N N N
14 contig00260:69016-71962(+) N N N N N N N
15 contig00052:839-1019(+) N N Y—6 N N N N
16 contig00071:75760-77446(+) N N N N N N N
17 contig00006:15286-16508(+) N N N N N N N
18 contig00156:32608..32875(−) N N N N N N N
20 contig00214:29581-33385(+) N N N N N N N
21 contig00047:67240-68739(+) N N N N N N N
22 contig00093:7841..7964(+) N N N N N N N
23 contig00130:22711..24075(−) N N N N N N N
24 contig00137:10059-13245(−) N N N N N N N
25 contig00088:68222-69173(−) N N N N N N N
26 contig00232:10901..11056(−) N N N N N N N
27 contig00433:34958-36380(+) N N N N N N N
28 contig00147:21973-23388(+) N N N N N N N
29 contig00145:9-1059(−) N N N N N N N
30 contig00167:23417-24638(−) N N N N N N N
31 contig00063:31158-31905(−) Y—50 Y—30 Y—65 Y—65 Y—65 Y—50 Y—65
32 contig00062:98497-98689(+) N N N N N N N
33 contig00079:101222-102015(+) N N N N N N N
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highly virulent feline pathogen that has never been iso-
lated/cultured in  vitro. Additional steps that should be 
taken in future studies include optimization and veri-
fication of the vaccination protocol prior to challenge, 
including verification of humoral immune responses 
by enzyme-linked immunosorbent assays or Western 
blotting.
One individual vaccinated with CF-Library (Cat 77) 
developed a comprehensive, albeit weak, serological 
response to vaccination, including a positive response to 
full length and the carboxy-terminal of cf76 (Additional 
file  8: Supplementary Fig.  4). Seven days post infection 
this cat’s antibody titers against all candidates decreased, 
suggesting that these antibodies may have been depleted 
during early infection (Additional file  8: Supplementary 
Fig.  4). Interestingly, this cat was the only individual in 
the study that only required minimal supportive care and 
no antiprotozoal therapy (Table 3). It is unclear if this was 
due to partial protection afforded by vaccination or due 
to this individual cat’s immune response.
Conclusions
In conclusion, we identified 30 new C. felis antigens via 
protein microarray. These antigens could be considered 
for use in development of diagnostic tests or therapeu-
tic interventions against C. felis. Bedside antigen detec-
tion tests are commonly used in veterinary medicine for 
rapid diagnosis of virulent disease [75], and monoclonal 
antibodies are emerging as a therapeutic tool against 
diseases afflicting veterinary patients [76]. Additionally, 
these antigens could still be considered for use in a vac-
cine against C. felis using a different vaccine platform.
Additional files
Additional file 1: Supplementary Data Set 1 Sequences of putative 
Cytauxzoon felis ORFs/genes selected for printing on protein microarray.
Additional file 2: Supplementary Table 1. PCR and cloning information 
for vaccine candidates.
Additional file 3: Supplementary Fig. 1. Cytauxzoon felis DNA vaccina-
tion pilot study design. A total of 18 cats were divided into four groups 
assessed in this study: three cats vaccinated with CF-1 prior to infection 
(red box), four cats vaccinated with CF-Library prior to infection (blue 
box), eight cats that were not vaccinated prior to infection (green box), 
and three cats that were neither vaccinated nor infected (gray box). The 
eight unvaccinated, infected cats were involved in a separate study test-
ing the efficacy of novel chemotherapeutics against cytauxzoonosis. If 
it became evident that vaccines or chemotherapeutics were not halting 
the progression of disease, cats were additionally given atovaquone and 
azithromycin to attempt to prevent death; these cats are noted accord-
ingly. A&A = atovaquone and azithromycin, 4X ABX = pradofloxacin, 
doxycycline, clindamycin, and metronidazole.
Additional file 4: Supplementary Fig. 2. Timeline of vaccination, infec-
tion, and sample collection for vaccinated cats.
Additional file 5: Supplementary Table 2. Additional clinical observa-
tions and information for individual cats.
Additional file 6: Supplementary Table 3. Summary of supportive care 
administered to individual cats. Cats vaccinated with CF-Library received 
less overall supportive care.
Additional file 7: Supplementary Fig. 3. Serological responses to C. 
felis antigens are increased during chronic infection. Serologic reactivity 
of antigens are depicted as a heatmap in (A). Antigens are listed in rows 
while grouping of individuals are denoted in columns. Average signal 
intensity of individual antigens against serum from acute and chronic 
groups are depicted in (B). The majority of antigens that had a higher aver-
age reactivity against serum from chronically infected cats (n = 50), but 
two antigens were more reactive against serum from acutely infected cats 
(n = 2, denoted with yellow boxes). These two antigens were incorporated 
into the CF-Library vaccine as Candidates 32-33.
Additional file 8: Supplementary Fig. 4. Serological profiles of individual 
vaccinated cats to candidates throughout study. Arrays containing the 32 
vaccine candidates included in CF-Library and in CF-1 were probed with 
sera samples from individual cats. Heat map shows normalized signal 
intensity with red strongest, white weakest, and gray intermediate. Rows 
denote 32 different candidates included in vaccines listed in descending 
order of reactivity; candidates 19 and 3 were included in CF-1, while all 
listed candidates were included in CF-Library. Results are organized by 
individual cats (identified by number at top), and survival status of each 
cat is indicated as “A” (alive) or “D” (dead). Individual columns within each 
cat’s array represent serum samples collected at different time points 
through study (labeled by the day in the study the sample was collected; 
refer to Supplemental Fig. 2 for timeline). There was no correlation 
between immunization protocol, individual reactivity, and survival for 
most cats, with the exception of Cat 77, who had widespread yet weak 
reactivity against all candidates in the CF-Library vaccine prior to infection 
and subsequently had milder disease and did not require supportive care 
or antiprotozoal therapy.
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